__timestamp | AstraZeneca PLC, AZN | Eli Lilly and Company, LLY | GSK plc, GSK | Takeda Pharmaceutical Company Limited, TAK |
---|---|---|---|---|
Saturday, October 1, 2022 | 0.080396181 | 0.2653729217 | 0.1980748373 | 0.1086379019 |
Sunday, January 1, 2023 | 0.1657321445 | 0.1932327586 | 0.2143576464 | 0.0325616322 |
Saturday, April 1, 2023 | 0.1592501752 | 0.2121244932 | 0.2262468654 | 0.0844450028 |
Saturday, July 1, 2023 | 0.119561434 | -0.0060429958 | 0.1796980484 | -0.046045927 |
Sunday, October 1, 2023 | 0.0798403194 | 0.2341073834 | 0.0434674615 | 0.0951415875 |
Monday, January 1, 2024 | 0.1718589794 | 0.2558052007 | 0.1420616596 | -0.0028719089 |
Monday, April 1, 2024 | 0.1489411037 | 0.2625013271 | 0.148782344 | 0.0788483348 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, financial performance is a key indicator of a company's health and strategic direction. This analysis delves into the net income margins of four major pharmaceutical companies—GlaxoSmithKline (GSK), AstraZeneca, Takeda, and Eli Lilly—over the past eight quarters.
Eli Lilly has demonstrated remarkable consistency, with an average net income margin of approximately 20.3%. Despite a minor dip to -0.6% in Q3 2023, the company rebounded strongly, reaching a peak of 26.3% in Q1 2024.
GSK has shown a steady upward trend, averaging a net income margin of 15.7%. The company peaked at 22.6% in Q2 2023, reflecting its robust financial health.
AstraZeneca's net income margin has fluctuated, averaging around 13.4%. Despite a low of 8.0% in Q4 2022, the company achieved a high of 17.2% in Q1 2024, showcasing its resilience.
Takeda has the lowest average net income margin at 5.2%, with significant fluctuations. The company faced a low of -4.6% in Q3 2023 but managed to recover to 10.9% in Q4 2022.
This comparative analysis highlights the financial dynamics of these pharmaceutical giants. Eli Lilly and GSK have shown strong and consistent performance, while AstraZeneca and Takeda exhibit more variability. Investors and stakeholders can leverage these insights to make informed decisions.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters